Library/For Long/SS-31 (Elamipretide)

FDA Approved (Barth, Sep 2025)For Long✓ Free to read

SS-31 (Elamipretide)

Also called Forzinity / SS-31

It guards the little power plants inside your cells (the mitochondria) from wearing out.

Updated 20 May 2026Read 4 minBacked by 60 studies

The quick version

What it is: A peptide that protects your cells' tiny power plants (brand: Forzinity)
Is it FDA-approved?: Yes, but only for a rare disease (Barth syndrome), since Sept 2025
How strong is the proof?: Strong for Barth syndrome. Weak or missing for everything else
How you take it: A shot under the skin
Typical result: Helps Barth patients. Unproven for healthy adults and anti-aging
Biggest catch: Hard to make right. Cheap research vials may be a fake, inactive copy

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

SS-31 is a very small , just 4 building blocks. Its drug name is elamipretide and the brand is Forzinity.

Inside your cells are tiny power plants called mitochondria. SS-31 sticks to a fat called cardiolipin in those power plants. That helps them work better and stay stable.

It got FDA approval in September 2025, but only for a rare genetic disease called Barth syndrome. It is the first mitochondria-targeting drug to get approved.

Heads up: this molecule has a special 3D shape that matters. A cheaper, wrong-shaped copy weighs the same but does not work. That makes it hard to check.

What people use it for.

The approved use is Barth syndrome, a rare disease in people who carry a specific gene.

People in the longevity and anti-aging world buy it off-label, hoping it boosts energy and slows aging. They often it with MOTS-c or Humanin.

That anti-aging use is based on the mechanism, not on proof it works in healthy people.

Does it actually work?

For Barth syndrome, yes. The approval is based on a real trial (TAZPOWER) plus a long follow-up.

For most other things, the record is mixed or negative. A trial in another mitochondrial muscle disease (MMPOWER-3) missed its main goal. A trial in dry eye disease (ReCLAIM-2) also missed its main goal.

So the story is honest but humbling: the idea kept looking good, but the trials outside Barth kept coming up short. For healthy adults chasing energy, there is no real proof.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

“It is FDA-approved now, so it is safe and legit.”

half true

The approval is real, but it is only for a rare genetic disease called Barth syndrome. The research vial you can actually buy is not that approved drug, and it carries its own identity problem.

“SS-31 boosts your energy and slows aging.”

unproven

That use is built on the mechanism, not on results in healthy people. Trials outside Barth syndrome, in another mitochondrial muscle disease and in dry eye, both missed their main goals. There is no real proof of an energy or anti-aging payoff.

“Cheap research SS-31 is the same molecule as the brand.”

SS-31 only works in one exact 3D shape. A wrong-shaped, dead copy weighs the same, so a basic mass spec test will not catch it. Without a chiral result on the , you cannot tell if the powder is even active.

“Stack it with MOTS-c and Humanin for full mitochondrial repair.”

myth

None of those have human proof of anti-aging benefit. Stacking three unproven peptides does not add up to a proven result. It just raises the cost and the number of unknowns.

How you take it.

In Barth syndrome, it is given as a shot under the skin, dosed by body weight.

People who buy research vials for off-label use inject smaller doses, often 1-4 mg a day. Its is about 2-4 hours.

If you run a research version anyway, give yourself a hard cutoff up front, say three months, tied to one thing you can actually feel, like daily fatigue or how long you last in the gym. No change by then means it is not doing the job for you. Running it open-ended just runs up the bill.

What to watch out for.

In trials, the most common side effects were mild reactions where the shot went in.

The bigger problem with research vials is identity, not side effects. SS-31's activity depends on its exact 3D shape (the "D-Arg" form). A wrong-shaped copy has the same weight, so a basic test will not catch it.

The only honest check is a special lab test called chiral . If a vendor cannot show that on the , you might be paying for an inactive look-alike. Talk to a doctor before using this. We are not your doctor.

Where people get it.

From safest to riskiest:

Brand (Forzinity). A real pharmacy drug, but only for diagnosed Barth patients. It costs over $200,000 a year through specialty pharmacy. Realistic only with insurance and that diagnosis.
. Not really available. There is no compounding path now that it is approved.
Research-only (). Sold "for research only," about $80-$300 a month. Highest risk. The wrong-shape copy is a real problem and the right lab test is rarely run.
. Overseas raw, about $25-$125 a month. Same shape problem as .

If you buy a research vial, demand a chiral result. Without it, you cannot trust what you got.

Our honest take.

The Barth-syndrome approval is real. The research vial you can actually buy may not be.

If you have a diagnosed mitochondrial disease and a specialist guiding you, this is a genuine drug with a genuine trial behind it. That is the narrow lane it earns.

For a healthy adult chasing energy, the trouble is not just thin proof. It is that you cannot tell what you bought. SS-31 only works in one exact 3D shape, and a dead, wrong-shaped copy weighs the same on a basic test. Unless the vendor runs a chiral check, you are paying research-vial money for a molecule you cannot confirm is even active.

That is the worst kind of bet: high cost, a real chance of an inactive look-alike, and no proof it helps a healthy person anyway.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

Learn about these too.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.